Women's Health Trial Tracker — 2004

Name: Women's Health Trial Tracker
Creator: 1 Women’s Health
License: United States government work; public domain unless the source record says otherwise.

Record	Record Date	Vuga Group	Change Status	Recency Days	Research Attention Score
Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.	12/14/2004	INTERVENTIONAL	not-comparable	7,970.75	0